CEO SUMMARY: In the absence of public discussion, continued use of the “free testing” strategy by the nation’s more aggressive laboratory companies could trigger some unpleasant consequences that would affect all laboratories and pathology group practices. Five questions, presented here, illustrate how private and public healthcare payers might react to the ongoing use of “free
Tag: billing medicare
EFFECTIVE AUGUST 27, Nasdaq Stock Market, Inc. delisted the stock of IMPATH, Inc. Less than a week earlier, IMPATH had disclosed that it was under investigation by the Securities and Exchange Commission (SEC).
IMPATH can truly be described as a company under siege. It is short of cash, under regulatory investigation, and defending itself from at
Will lab information system services be a value- added selling point for the national reference labs? Developments at American Medical Laboratories (AML) and Specialty Laboratories would indicate yes. First, AML entered a strategic alliance with Park City Solutions to develop e-commerce solutions targeted at healthcare and laboratory services. Now Specialty Labs has recruited Jack Redding